Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat for delaying chronic kidney disease progression
ChiCTR2200061138Phase 4Not yet recruiting
- Sponsor
- PLA Army Specialty Medical Center
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of roxadustat in chronic kidney disease (CKD) and anemia of chronic kidney disease, sponsored by PLA Army Specialty Medical Center. Primary endpoints: eGFR and Serum creatinine. Planned start May 2022; status: not yet recruiting.
02
Drugs
roxadustat
03
Conditions
chronic kidney disease (CKD)anemia of chronic kidney disease
Beyond the preview
Go deeper on ChiCTR2200061138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061138.